Traynor Capital Management’s Vertex Pharmaceuticals VRTX Stock Holding History

Traynor Capital Management’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$5.23M	Buy	11,806 +39	+0.3%	+$18.2K	0.31%	55
2025 Q4	$5.33M	Sell	11,767 -198	-2%	-$85.3K	0.28%	54
2025 Q3	$4.69M	Buy	11,965 +290	+2%	+$121K	0.27%	57
2025 Q2	$5.28M	Buy	11,675 +631	+6%	+$291K	0.37%	41
2025 Q1	$5.35M	Buy	11,044 +5,282	+92%	+$2.46M	0.45%	42
2024 Q4	$2.32M	Buy	5,762 +5,256	+1,039%	+$2.44M	0.16%	74
2024 Q3	$235K	Buy	+506	New	+$243K	0.01%	212

Other funds holding VRTX

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Traynor Capital Management's VRTX Position: Q1 2026 in Review

Traynor Capital Management increased its Vertex Pharmaceuticals (VRTX) stake by 0.33% in Q1 2026, buying an estimated $18.2K and bringing the position to 11,806 shares worth $5.23M. The position accounts for 0.31% of the portfolio, ranked #55.

Traynor Capital Management first reported a position in VRTX in Q3 2024 and has held it in 7 quarters since. The position peaked at $5.35M in Q1 2025. 1,687 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.

Traynor Capital Management held 11,806 shares of Vertex Pharmaceuticals worth $5.23M as of Q1 2026.
Traynor Capital Management bought 39 Vertex Pharmaceuticals shares in Q1 2026, an estimated $18.2K.
Vertex Pharmaceuticals made up 0.31% of Traynor Capital Management's portfolio in Q1 2026, its #55 holding.
Traynor Capital Management first reported a position in Vertex Pharmaceuticals in Q3 2024 and has held it in 7 quarters since.
Traynor Capital Management's Vertex Pharmaceuticals position peaked at $5.35M in Q1 2025.
1,687 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.

Based on Traynor Capital Management's 13F filing for Q1 2026, filed 15 May 2026.